EANS-Total Voting Rights: Intercell AG / Release according to article 93 BörseG with the aim of a Europe-wide distribution

--------------------------------------------------------------------------------
Total number of voting rights announcement transmitted by euro adhoc. The
issuer is responsible for the content of this announcement.
--------------------------------------------------------------------------------

Intercell AG hereby announces that at the end of the month June 2012
the number of voting rights amounts to a total of 55.183.961 voting
rights. The change of total voting rights is effective as of
01.06.2012.

additional (optional) statements: Intercell closes previously
announced capital increase Announcement of the total number of voting
rights according to section 93 subsection 1 of the Austrian Stock
Exchange Act

Vienna (Austria), June 1, 2012 – Intercell AG (VSE: ICLL) today gave
notice of the completion of the capital increase of 6,591,742 shares
which was previously announced on May 14, 2012. The shares had been
placed in an equity private placement transaction at an issue price
of EUR 2.30 per share. Following registration in the Commercial
Register, the new shares have now been issued and will start trading
on the Vienna Stock Exchange today.

According to section 93 subsection 1 of the Austrian Stock Exchange
Act, the management board makes the following announcement: The total
number of shares of common stock with no par value of Intercell AG,
each representing one vote, has increased to 55,183,961. The share
capital is now EUR 55,183,961.

The proceeds of the private placement were approximately EUR 15.2
million. The new shares represent 11.9 percent of Intercell’s total
share capital following the completion of the capital increase.

The equity private placement was part of a combined debt and equity
financing of approximately EUR 35.2 million, consisting of a EUR 20.0
million loan provided by BB Biotech and the equity private placement
of approximately EUR 15.2 million, in which BB Biotech participated
in respect of EUR 5.0 million. Intercell’s biggest shareholder
Novartis participated in the equity private placement pro rata by
maintaining its 14.9 percent stake in the Company. Both the equity
and the debt component have now closed.

end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: Intercell AG
Campus Vienna Biocenter 3
A-1030 Wien
phone: +43 1 20620-0
FAX: +43 1 20620-800
mail: investors@intercell.com
WWW: www.intercell.com
sector: Biotechnology
ISIN: AT0000612601
indexes: ATX Prime
stockmarkets: official market: Wien
language: English